HIMS & HERS Aktie

 

HIMS eyes long-term growth with new hormonal health offerings, international expansion and high GLP-1 retention....

Charlotte, NC (www.aktiencheck.de) - Hims & Hers-Aktienanalyse von Truist: Die Analysten von Truist senken das Kursziel für die Hims & Hers-Aktie (ISIN: US4330001060, WKN: A2QMYY, Ticker-Symbol: 82W, NYSE-Symbol: HIMS) von 48 auf 37 USD und belassen ihr Votum auf "hold". Die Intra-Quartalsdaten der Truist Card würden darauf hindeuten, dass die GLP-1-bezogenen Umsätze des Unternehmens im Quartal anziehen könnten, mit einem weiteren moderaten Anstieg im vierten Quartal, der weitgehend durch die Realisierung aufgeschobener Erlöse getrieben werde. [mehr]...

Die Online-Apotheke GoodRx hat einen Deal mit Novo Nordisk an Land gezogen: Das Unternehmen tritt die Nachfolge von Hims & Hers an. Die Aktie explodiert.Jetzt den vollständigen Artikel lesen...

NEW YORK, Aug. 18, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the "Class Period"), of the important August 25, 2025......

NEW YORK, Aug. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS). Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff......

Novo Shares Gain As Wegovy Wins FDA Approval For Liver Disease Novo Nordisk shares gained in Copenhagen trading on Monday after the U.S. FDA approved Wegovy for the treatment of metabolic-associated steatohepatitis (MASH), a severe form of liver disease. The approval gives Novo a first-mover advantage over Eli Lilly in the U.S. market.  Year-to-date, Novo shares have lost nearly 50% amid intensifying GLP-1 competition, including Eli Lilly's obesity drug Zepbound and copycat threats (GLP-1 compounds) from companies such as telehealth company Hims & Hers Health. The MASH approval offers a potential incremental growth driver and could reverse some of the negative sentiment surrounding the stock this year. This raises the question for investors whether current stock levels represent a buy-the-dip opportunity.  The FDA's decision marks the second positive news for Novo this month, following Lilly's oral obesity pill, orforglipron, that met its primary endpoints but fell short of Wal...

LOS ANGELES, Aug. 18, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims & Hers" or "the Company") (NYSE: HIMS) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses......

LOS ANGELES, Aug. 18, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Hims & Hers Health, Inc. ("Hims & Hers" or "the Company") (NYSE: HIMS) for violations of §§10(b) and 20(a) of the Securities......

Ten large-cap stocks, including CRWV, COHR & AMZN, were the worst performers last week. Weak results, downgrades, and FTC probe may be the reasons. read more...

RADNOR, Pa., Aug. 17, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc.......

SAN DIEGO, Aug. 17, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, inclusive (the "Class Period"), have until Monday, August 25, 2025......

NEW YORK, Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.......

Okupe, Oluyemi - Vorstand - Tag der Transaktion: 2025-08-13...

BENSALEM, Pa., Aug. 15, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS). IF YOU ARE AN......

NEW YORK, Aug. 15, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ("Hims & Hers Health, Inc." or the "Company") (NYSE: HIMS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Hims & Hers......

Nach einem Bericht über eine laufende FTC-Untersuchung ist die Aktie des Telemedizin-Anbieters von Hims & Hers im nachbörslichen Handel deutlich eingebrochen. Was genau ist passiert?Jetzt den vollständigen Artikel lesen...

PHILADELPHIA, Aug. 14, 2025 /PRNewswire/ -- Berger Montague, a national securities litigation law firm, is investigating potential securities fraud claims against Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). Investor Deadline: Investors who purchased or acquired......

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

For more than a year, the Federal Trade Commission has been investigating Hims & Hers Health Inc.'s business practices, including whether it has made it too hard for customers to cancel subscriptions, according to people familiar with the probe....

Insider moves in IonQ, Hims and Hers, Eli Lilly, and TransMedics reveal bold buys, record sales, and signals worth watching....